An award-winning artist brought together a community to create a patchwork blanket using petals from two National Trust gardens.
Salma Zulfiqar invited school pupils and people from marginalised communities to create patches for the biodiversity blanket made from pressed and dried flowers from Packwood House and Baddesley Clinton on the border of Solihull and Warwickshire.
“We had almost 100 people working on this, so each piece you see if a reflection of their learning in the workshops that we did,” she said.
Ms Zulfiqar worked with Packwood’s head gardener over the last six months to gather, dry and press flowers for the project.
“We collected lots of flowers from the grounds which have medicinal value, and used them in the workshops to create the sections, which we call petals,” she said.
“We wanted the blanket to reflect all of the beautiful flowers you can find at Packwood and help people learn about their value.
“I worked with young women from around the area and it gave them an enjoyable experience and help bring them together as a community.”
A National Trust spokesperson said the flowers which were selected from the gardens were chosen because they are “useful as well as beautiful”.
“Examples of this are pressed catkins from hazel plants – corylus avellena which produce edible hazelnuts and pressed hellebore flowers which are the source of compounds which are being researched as potential future medicines,” they added.
[Sponsored] Combining a 3D art gallery and marketplace with a supportive user community, RenderHub is an online destination for anyone serious about their art – and serious about developing their art career. Four RenderHub users share their thoughts on what makes it special.
Today’s 3D artists are looking for more than just a place to post their artwork. They want meaningful exposure, a real community, and tools that help them grow professionally.
The RenderHub 3D gallery offers all of this. It is not only a digital space to display images but also an online hub of activity where creators connect, share, and evolve together. This article takes a closer look at what makes this such a valuable platform. It also features insights from four talented artists who have chosen to make this website their creative home.
Creating a 3D art gallery that reflects your style
Getting started on RenderHub is as simple as setting up your profile and uploading images to your gallery. This personal space acts as a dynamic portfolio, allowing others to explore your artistic journey over time. Whether you specialize in detailed Blender models, cinematic scenes, or stylized characters, the gallery is designed to allow you to represent your unique style. A professional presentation allows your images to stand out in a crowded field.
Once you have created your profile, RenderHub’s intuitive tagging system makes it easy for viewers to discover your work while they browse 3D renders or search for something specific. This feature helps you connect with potential buyers, collaborators, and fans more effectively.
Inside a 3D artist community focused on growth
Engaging with other people is the next step toward success. Unlike static portfolio sites, RenderHub encourages interaction. Members can comment on each other’s artwork, take part in discussions, and follow one another to build meaningful connections.
This creative community makes it easy to learn from others while also being inspired by the wide variety of styles on display. As you browse the gallery and discover other 3D artists, you’ll find new ways to challenge yourself and refine your craft.
RenderHub offers more than visibility: it also offers support and connection. As member maru_berlin explains:
“After more than 15 years of showing my renders on various websites, I found RenderHub an excellent community to be part of. It’s a friendly place with a thankfully growing number of artists and vendors.”
Let Me Help You by maru_berlin
Why consistency matters in a 3D art showcase
Many artists find that consistency plays a key role in building visibility on RenderHub. Members who post regular updates benefit from increased exposure and engagement. By uploading new artwork frequently, your gallery stays active and relevant. This steady rhythm not only helps your portfolio grow but also keeps you connected with a wider audience.
GMArtworks is one of the artists who takes full advantage of this approach:
“My experience with RenderHub is great, and I feel at home in the community. The RenderHub team is very helpful if you have a question. I also get the opportunity to sell my 3D models, and I’m very happy with that.”
Three Chimpanzees Look into the Camera Lens by GMArtworks
Earning income and recognition with 3D skills
RenderHub is more than just an online community for digital art. It also includes an integrated marketplace where creators can upload everything from single models to complete scenes.
Selling your 3D assets in the marketplace can help you turn your passion into profit. Members also gain access to regular features and cash-prize competitions that reward creativity and increase exposure. These opportunities make RenderHub a great answer to common questions artists have – like “where can I upload and showcase 3D artwork?” or “what’s a good online gallery for Blender artists?”
MysticArtDesign describes how the platform supports their professional goals:
“As an artist, it’s especially the competitions that make you feel valued. If you’re good, you’ll be rewarded. They also make it easy to connect with others and have valuable exchanges. And as a content creator, the marketplace is very convenient and easy to use. All in all, I feel very comfortable at RenderHub.”
Kawaii Anime by MysticArtDesign
Growing a 3D audience to reach more people
With a combination of intuitive community features and a robust marketplace, RenderHub members have powerful tools to expand their reach. The website allows creators to present their artwork online in a professional and organized way, making it easier for viewers to explore and appreciate their portfolio. This increases visibility, and with the connected marketplace and forum, it creates multiple avenues for engagement. Artists can attract clients, customers, and fans from around the world, building a dedicated audience that grows over time.
This combination has been key in helping Khatri3d build momentum and sales potential:
“My experience with RenderHub has been very pleasant from the start. Their core marketplace structure and gallery system, which help expose artists and increase sales potential, have worked well for me. The customer service is excellent compared to other marketplaces. Whenever I have an issue, I receive a direct response from the admin within 24 hours.”
Albert Einstein 3D Caricature by Khatri3d
What draws 3D artists to RenderHub
RenderHub is a destination for 3D artists who are serious about their work and growth. It combines the visibility of an online art gallery with the support of a friendly and engaging creative community.
Whether you’re just starting or have years of experience, RenderHub provides the tools and opportunities you need to thrive. From sharing renders and learning new techniques to selling assets and competing in contests, artists can take full advantage of everything the platform has to offer. For anyone looking to grow in the digital art space, the 3D gallery at RenderHub is a place where creativity and community come together for you.
Six ribs broken in 14 places. Three breaks in the lower pelvis. Right and left ankle broken. Left tibia broken. Left wrist fractured. Left toes, three breaks. Right clavicle broken. Right shoulder blade cracked. Eye socket, jaw, mandible, all broken. Major laceration back of head. Lung collapsed. Liver pierced from rib bone. The inventory of Jeremy Renner’s injuries, documented by the twice Oscar-nominated movie star himself, was exhaustive. It was a miracle that the actor had survived; he had no right to. Renner had been crushed by his own 14,000lb (6,350kg) snowplough on New Year’s Day 2023. A neighbour who helped him at the scene believes he died momentarily. So does Renner. He tells me it was a very special moment.
“What I experienced when I passed was this collective divinity and beautiful, powerful peace. It is the most exhilarating peace you could ever feel. It’s the highest adrenaline rush. Everything stopped … maybe for 30 seconds, maybe a minute. It was definitive for me. It all made perfect sense.” Does he believe in God? “No. My dad’s a theologist and I studied all religions growing up, so I steer away from religions.”
Today, Renner is sitting in front of me in a London hotel, very much alive, looking fit, flawless and grateful. He’s written a memoir, My Next Breath. It’s not simply the story of surviving against all odds, it’s the story of a man who found a new sense of purpose in extremis. “Being here to talk about my book is so different from having to talk about Mission: Impossible!” he says before he’s even sat down. What’s the difference? “Well, we’d be talking about stunts and the joy of being in a big action movie with one of the biggest stars around, Tom Cruise.”
However much enthusiasm he tries to muster for chatting about the Mission: Impossible franchise, it’s obvious which subject he prefers. “The big difference is fiction and nonfiction. I have a real issue now with fiction. I don’t have much time in my life for it, having come back from such a pretty harrowing experience of real reality. I have to focus on reality even though I play make-believe for a living. I have to really believe in my recovery to walk again right and to breathe again right and to love and … experience … and …” He trails off, a fog of words disappearing into the ether.
Has that created an existential crisis – being an actor who doesn’t want to act? “I had a battle with that, because a year ago my real battle was with just walking, right? I had to focus so much energy just on walking.” He mumbles some more – think Elvis in Vegas. I catch half-sentences about making series two and three of the Mayor of Kingstown, in which he plays rock-hard powerbroker Mike McLusky, learning to trust his body again, getting used to the real world.
Renner posts a selfie from his hospital bed days after his accident in January 2023. Photograph: Jeremy Renner Instagram
Renner is a classic mumblecore actor. Not quite the full Brando, but he’s good. In films it gives him an easy naturalism and, often, a scary authenticity. In an interview situation, when you’re hanging on to every word, it can be frustrating. It’s not surprising that he was cast as a superhero in The Avengers films and its spin-off TV series Hawkeye. He looks like one – small, strong, compact; a nine-volt battery of a man. In so many movies, he plays the toughest in a group of toughies. Despite his size, he’s the one whom the big guy messes with at his peril. Renner’s characters are often reckless adrenaline junkies on the cusp of crazy.
He is the first person to admit that despite huge success playing these rock-hard superheroes, rock-hard military men (The Hurt Locker, which earned him a best actor Oscar nomination in 2010), rock-hard criminals (The Town, which won him a best supporting Oscar nomination a year later), rock-hard black ops agents (The Bourne Legacy) and rock-hard analysts (Mission: Impossible), he wasn’t the happiest of bunnies. He often grumbled about his work, hated being away from his daughter Ava, and had recently been involved in a humiliating public divorce in which all sorts of allegations were slung at him.
For most of the time, he just wanted to be at home relaxing with his huge extended family (Renner is the oldest of seven siblings), his friends, and most of all Ava. Which, ironically, is what he had been doing when the accident happened. He had driven over from his former home in the Hollywood Hills to his residence near Reno, Nevada, which he calls Camp Renner. This was where the family would meet to mark special occasions and enjoy skiing and snowboarding.
The six-acre estate at Lake Tahoe sits 7,300ft above sea level on a private road off the Mount Rose Highway. Renner renovated the property himself after buying it in 2012 (he has had a lucrative and satisfying sideline in renovations – or Rennervations, as he calls them – throughout his acting career).
Photograph: Sebastian Nevols/The Guardian
On 30 December 2022, the Tahoe Daily Tribune reported that there could be up to 5ft of snow and the forecast had been upgraded to a winter storm with gusts possibly exceeding 100mph for Sierra ridges. By 31 December, they had no mobile phone service and no internet at Camp Renner, and they were snowed in. But with the help of his tank-like snowcat, they were still hoping to ski on New Year’s Day. The snowcat is an industrial snow remover – a cab sits above six sets of heavy wheels and two sets of galvanised steel tracks made up of 76 blades that extend outward beyond the body of the vehicle.
It was 6am when Renner jumped into the snowcat. He was hoping to clear the driveway and dig out the parked vehicles. It was a big job, so he asked his 27-year-old nephew Alex to help him. Once they were done with the driveway, they’d be fine – the main road had already been ploughed. They had cleared most of the snow when Renner got out of the snowcat to have a word with Alex. That’s when the vehicle began to slide on the icy asphalt. Renner realised he hadn’t put the brake on. The snowcat was heading straight for Alex, who was trapped between the monster machine and a pickup truck. The only chance to save his nephew was to leap across the snowcat’s 3ft metal tracks and up into the cab and hit the stop button. He remembers shouting, “Not today, motherfucker”, as he thought Alex was about to be crushed to death. The response of an action hero.
Renner missed the cab. He was catapulted forward, off the spinning metal tracks, on to the ice. The snowcat continued to charge forward, and over him. “There came terrible crunching sounds as 14,000lb of galvanised steel machinery slowly, inexorably, monotonously, ground over my body. It was a horrifying soundtrack,” he writes in My Next Breath. “Skull, jaw, cheekbones, molars; fibula, tibia, lungs, eye sockets, cranium, pelvis, ulna, legs, arms, skin; crack, snap, crack, squeeze, crack. More sounds: a ringing in the ears, as if a large-calibre gun had unloaded next to my head. A sting of bright white in my eyes – I am blinded by a coruscating lightning, a lightning that signals the break of my orbital bone, causing my left eyeball to violently burst out of my skull.”
It felt like an eternity, but within a few seconds the snowcat had passed over him. It was still surging forward, but Alex had managed to get out of its way. Would the snowcat have hit Alex if he’d not intervened? “It’s hard to say. You’ve not got time to make a rational decision. You just do it. The worst scenario is that he is crushed. So I just had to act. There was no way I was going to take that risk and see my nephew’s head on the ground cut in half. No chance. I’m not doing that. I’m not taking the chance, so that’s why I’d do it again in two seconds.”
Renner’s still not sure how he survived. So many factors played a part. He cites the Lamaze breathing class he went to aged 12 with his mother when she was pregnant; he went on to use the technique in auditions or when he was stressed. Renner used to have a placard on the wall in his apartment saying “Don’t forget to breathe”. But at the time of the accident, the act of doing so was excruciating. As he struggled for oxygen, carbon dioxide built up in his lungs and bloodstream, and he felt that he was drowning. On the recording of his neighbour’s emergency call you can hear Renner trying to breathe. Each guttural groan sounds like a death rattle. One technique he used was to repeat the expression “hookers, whores and hamburgers” in a mantra-like way, because the huffing of the “H” forced him to work his lungs.
His two neighbours, Rich Kovach and Barb Fletcher, whom he had never met before, stayed with him, keeping him alive as he lay in a pool of blood. Alex sat on his haunches, holding up Renner’s smashed arm to prevent it flopping into his crushed rib cage and punctured lung and stopping him from breathing. Renner’s left eye had landed on the ice; he could see it with the eye that was still in its socket. (Amazingly, he could also still see with the eye that was hanging out.) Dark thoughts began to intrude. “Am I going to live like I’m in some kind of petri dish, a fucking science experiment? Will I just be a brain inside a ruined body? A vegetable.” And yet part of him thought if he could just ease the cramp, he’d be able to walk back to the house.
Meanwhile, Fletcher held his head and kept talking to him, desperate for him not to lose consciousness. “Just keep breathing,” she told him. “Just take shallow breaths. Stay with us. Keep your eyes open.” It was Fletcher who was holding him when he went clammy and his skin turned green-grey.
Renner tells me today that so much of it was down to willpower. “I was bullying my body into thinking it wasn’t that bad and my mind was overcoming the greatest odds it’s ever come up against. My mind was saying, ‘Nah!’ It was part stubbornness. ‘I don’t want to lose this battle, this game’, but the deeper part, the zoomed-out part, is I had so much to live for. I had a bunch of people waiting for me to go skiing!” He smiles. He knows it was a ridiculous thing to be thinking, but it kept him going. “I didn’t want to let them down. That became such a big thing.”
Photograph: Sebastian Nevols/The Guardian
But, of course, there was more to it than willpower. Last year, he released his second album of largely self-penned songs. Love and Titanium is about the accident, and so called because these are another two things that have helped him pull through – the love of family and friends, and the titanium that has helped fix all those broken bones. He was also extremely lucky. Nobody gave him much hope at the time – Alex, Kovach and Fletcher, the medical team who helicoptered him to hospital, the paramedic who pierced his chest cavity to enable him to breathe more easily, all thought he was a goner. “That guy who impaled my chest to release the pressure was a friend of a friend, and he called my friend after he did it and he said, ‘We did the best we could.’”
Almost as amazing as his survival was the fact that he only stayed 12 days in hospital. In fact, high on morphine and fentanyl, attached to drips and unable to walk, he tried to escape far earlier. “It was the slowest breakout ever,” he says, laughing. As he talks, I’m looking him up and down for signs of damage. Nothing. Eventually I spot an elegant circle around his ankle. It looks more like a bracelet than a war wound. Is that a scar, I ask. He nods. “I have a bunch of little scars, but only from the surgery to save my body. The whole leg is titanium from the knee down to the ankle.”
Is he still in pain? “My mouth is still complete chaos.” Let’s have a look, I say. He opens wide, obligingly. “It looks fine, but when I bite down it feels as if I’m going to break all my teeth.”
As an actor, Renner was famous for his athleticism and suppleness. Like Cruise, he did his own stunts. Are there things he can no longer do? “I don’t know. In my mind no, in my body probably. I’m also 54. But my mind still thinks I’m 20.”
The first song on Love and Titanium is called Lucky Man. “One day you just wake up / And finally realise / Life is so god damn beautiful / And I ain’t got nothin’ left to lose.” Renner tells me that it took him the accident to realise just how beautiful life was. Now, he says, he wakes up and knows he’s not going to have a bad day. No day alive is a bad day. But it didn’t used to be like that.
Some people are natural celebrities. Renner is not one of them. He struggled with his fame. In the TV series Hawkeye, there’s a scene where his eponymous superhero is in a public toilet, and the man peeing next to him asks for a selfie. He says this happened to him in real life. At airports, he would often eat his meals in the toilet cubicles to avoid the public. He loathed the way some fans thought they had a right to his time whatever he was doing. And then there was the way people assumed they knew him, though they tended to talk to him as if he was the character they’d last seen him playing. He felt it was diminishing. “As a celebrity, you’re a product and you’re viewed as a bunch of different things. I might be Hawkeye to somebody, I might be this to somebody else, but I’m still a man; just a human eating spaghetti with my daughter.”
Renner in TV miniseries Hawkeye, 2021. Photograph: Chuck Zlotnick/Image supplied by Capital PicturesWith Tom Cruise in Mission: Impossible – Rogue Nation, 2015. Photograph: Paramount/Everett/Shutterstock
That’s all changed. He loves the way people now talk to him as Jeremy Renner, the man who survived a terrible accident. He feels people can relate to him, at last. We might not have been run over by a 14,000lb snowplough, but all of us have experienced bad luck in one form or another. “There’s a beautiful intimacy and openness and vulnerability and kindness and thoughtfulness I get from people now, instead of just taking their deserved selfie. It’s a different human exchange. I think it’s given them a pathway. They feel, ‘He’s a human just like I am.’”
skip past newsletter promotion
after newsletter promotion
I tell him that I like the honesty of his book. He writes that he was a man who was hard to love. At times he comes across as grumpy, churlish and antisocial. Has that changed? “I think all the parts of the recipe that made me are still there. But I don’t think I have much time to be grumpy now.” Why was he so grumpy? “I was dissatisfied with a lot of things in my life.” Such as? “Not having my life!” In what way? “I was the one putting all the obstacles in my way. By obstacles I mean jobs. I was wildly successful, and I wanted to take advantage of every opportunity I would get. But it wasn’t healthy for a balanced life. Four birthdays in a row I didn’t see one family member. You’re always doing amazing things – Avengers, The Bourne Legacy and all these great big movies. Awesome! But the dissatisfaction was not being with those I love.”
With Anthony Mackie in The Hurt Locker, 2008. Photograph: Ken Regan/THA/ShutterstockWith Rachel Weisz in The Bourne Legacy, 2012. Photograph: Universal/Everett/Shutterstock
Why did he keep doing it if it made him unhappy? “I knew there was going to be an ending to this stuff. So I had to put these franchises as the priority. I caught fire from The Hurt Locker and then all these great opportunities came along. It was the Academy Awards two years in a row, my mom was my date, all these great blessings, and that was great. But only when the movies came out did I really get to see my family [for the premieres]. There are 25 of us. A bus has to come and pick up the family, but I was still missing out.” And when he wasn’t making movies, he was renovating houses. “I built 26 homes in 20 years. And my music was also a priority. So I had all these things spinning. I just know where my priorities lie now, and nothing can get in their way at this point.”
Renner comes across as supremely competitive in the book. In the 1980s, his father managed a bowling alley in Modesto, California where the actor grew up. By the age of 12, he says, he was good enough to bowl against professionals in a competitive league. But that wasn’t enough for him. He wanted to be the best, and when he wasn’t he went into meltdown. “Self-doubt turned into hatred, hatred into anger, anger into rage,” he writes. In the end, he walked away from bowling.
He also makes it clear that he always expects the best from those around him. When he feels disappointed by friends or family members, he’d give them a good, sharp Renner Talk, “where I challenge people to improve, to commit harder, to face their failings and be better, to not be afraid”.
He has given himself plenty of Renner Talks over the years. Throughout his 20s he challenged his fears. Anything he was frightened of, he took on, whether it was fear of success, intimacy, snakes or heights. In the case of sharks, he got a scuba diving licence, then a master diver’s licence and went swimming with them. Ultimately, he says, nothing scared him.
Is he as tough as the characters he plays? “I think I’m softer.” He mulls it over. “I’ve got my mom’s toughness. She has this inner strength, this fortitude.” What about the physical toughness? “Yeah, I get that from her as well. She was an athlete. I also have the soft, curious mind of my father.”
At times, you sound terrifying, I say. I read an interview in which he talked about having to “choke out” men when they were causing him bother. He gives me a butter-wouldn’t-melt look and giggles. “The family do like having skill sets, like the girls like to do wrist locks and know how to throw a throat punch. I’ll show them how to do these things.” But no, he says, he wouldn’t do anything violent – in fact, he does the opposite. “So if somebody is acting hysterical I just touch them, and they’re like, what happened? I get their attention by touching their throat. It’s like giving someone a hug when they’re mad at you.” And he gently taps his throat by way of illustration.
I’m a bit flummoxed. Perhaps I’m confusing him with somebody else. When I get home, I check old interviews with Renner, and sure enough there it is in a 2015 Playboy piece when he says: “This guy got really drunk and pushed Julia Stiles, my co-star [in the 2005 movie A Little Trip to Heaven]. I kindly choked him out and remedied the situation. I’ve also had to choke people out because they pushed my mom or knocked my sister down, but I’ve never felt like a badass.”
Photograph: Sebastian Nevols/The Guardian
Renner is famous for outre comments. In 2015, he and Jennifer Lopez presented the best actor in a television mini-series award at the Golden Globes. Lopez offered to open the envelope. “You want me to do it? I have the nails,” she said to Renner. “You got the globes, too,” he replied, staring at her chest. While many people on social media lambasted him for the comment, he told Playboy: “Actually, Jennifer thought it was fucking funny and got a little sweaty and maybe even turned on by the whole experience. Other people started running their mouths about it. Everybody’s entitled to an opinion, but I can’t be bothered. We gave zero fucks.”
In 2019, Renner met more controversy when court custody filings became public. The actor Sonni Pacheco, 20 years his junior, filed for divorce in 2014 after they had been married for 10 months, but details of their long-running custody battle didn’t emerge till five years later. Pacheco asked for sole custody, saying Renner was an “unfit parent”. She claimed he had talked about killing her and then taking his own life, and that he had bitten Ava’s shoulder. Renner described the allegations as “dramatisations” made with a “specific goal in mind” and denied biting Ava, saying the mark was from a car seatbelt that “pinched” her.
Other people provided statements in support of Pacheco. There were claims that he had put out lines of cocaine on a bathroom counter within Ava’s reach and left her unsupervised for hours. One woman admitted to having a threesome with him, and says she saw him pass out drunk. She said she was shocked when she discovered that Ava had been in the house all the time, at one point coming down the stairs to look for him. Another said she’d seen him put a gun in his mouth and fire it at the ceiling.
In the book, he describes himself as a “cranky, cynical, grubby cat motherfucker”. We’ve heard about the crankiness. Where does the cynicism come from? Spending too long on the east coast, he says. “I think it’s where innocence gets lost or weathered. It’s like east coasters will have more of a mental toughness and their sense of humour is rougher around the edges. More aggressive. You bust each other’s balls, that kind of thing.” And what about the “grubby cat motherfucker?” He bursts out laughing. “The phrase alone makes me giggle. I don’t take myself very seriously. Whatever stress I’ve had in life I’ve tried to find a way of laughing through it. And that’s where sometimes cynicism comes out – you think, I’m just going to have a laugh at this stuff.” What stuff? “Being accused of things you’ve not done, right? That doesn’t feel good to anybody. It certainly doesn’t feel good when you’re a celebrity and it’s known to everybody.”
Are you talking about the allegations in the media at the time of the divorce? “Yeah. Yeah.” Is there any truth in them? “No, and they happen all the time. It’s all the salaciousness that happens out there. It’s clickbait, and it hurts my feelings and it dehumanises people.”
To be fair, I say, you do sound as if you were a party animal. He gives me another butter-wouldn’t-melt look. I mention the stories of threesomes, drugs and boozing. “That’s not really my style,” he says. Really? “People say whatever.” Then he starts to explain. “Look, I live a carnival-type life. I don’t live a normal life. The amount of travel I have done, always living in a suitcase.” And when he was home in LA, he says, he didn’t go out because he was too well known, so he socialised at home. “The place in LA was where I was raising my child, where everyone learned to ride a bike and swim. I also had my music there. I had my meetings there. It was my dating life. It was my club. It was my home. It was all the things that encompass someone’s life. If you meet a person and grab a pint, instead of meeting up at a pub, I’d just do it at my house. It was like an open-door policy for all my family and friends. It was great for them. So that’s not a normal home. Homes aren’t usually like that or run like that way. So that’s no longer.” The way he describes it, it was both a nursery and a night club, and sometimes little distinction was made between the two.
That’s the party lifestyle I was talking about, I say. “Yeah, yeah. Hosting. I just got tired of hosting. And all the clean-up. Hehehe! So by 2019 I was tired of all that. Covid came around and helped me bounce that all out. I just wanted to slow down.”
How did he feel when the allegations emerged? “It doesn’t matter to me what people say,” he says before the question is fully out. “They’re saying it for their own reasons and not for the right reasons or the truth. And I’m used to that, because I’m a public figure. I don’t read people’s reviews, I don’t read people’s comments. I don’t care. That’s not part of my life.”
Ava clearly means so much to him. He now has joint custody with Pacheco, and the book is dedicated to his daughter (“my lifeforce … my everything, my only thing, my number one”). I ask if he feared losing her in the custody battle. “That’s just lawyers talking. That’s lawyers arguing. The custody was easy.” And then he says something surprising. “Her mom and I get along very well, and we’re in each other’s lives. It’s lovely.” Wow, I say – I had no idea. “Yeah, yeah,” he says, enthusiastically. I’ve never read that before, I say, tell me about it. “Well that’s because it’s no one’s business. It’s no one’s business.” True, I say, but then you just read the horror stories. He softens. “It’s great. She’s got a new baby and she sends me beautiful pictures.”
Photograph: Sebastian Nevols/The Guardian
Has he currently got a partner? “No, not at the moment.” (Last year, it was reported that he was dating CC Mason, a fashion journalist 28 years his junior.) A relationship is not a priority at the moment, he says. “I’m pretty focused on my daughter and the foundation for the kids.” The foundation, also called RennerVation, provides support for at-risk children and those in foster care. Shortly before the accident, he made a Disney+ series about his project renovating old school buses to meet a community’s needs, and out of that came the nonprofit foundation.
Rather than acting, this seems now to be his life’s mission. “That’s where the accident’s really shifted my focus. I can still go to work, but my primary focus is to give back and help in any way I can. That’s way more fulfilling than anything else I’ve done, outside bringing up my own child. Being able to put a smile on these kids’ faces and share that joy with them and share the growth, I can’t think of anything more rewarding.”
He feels so much more at one with the world, he says. Take the book. The last thing the old Renner would have wanted to do is share such a traumatic experience. But the accident has led him into a different way of thinking, and now he couldn’t be happier he’s written the book. “It forced me to get out of my own way of being private and a recluse to share something.” You’ve been forced back into the real world? “Yeah. I’ve never been more connected and more open and more vulnerable and more loving. And I’ve never received more goodwill. That connection was buried deep, deep, deep in my soul, beforehand, but now it’s at the forefront. It’s all that matters to me.” He takes a deep breath – long, leisurely and content. “It’s an honour to be alive,” he says.
I am obsessed with sharks. Fifty years on from Jaws, and for me no film can touch it. I trawl YouTube for unspeakable footage. On a recent holiday to France, I made my nonplussed household watch every shark documentary on National Geographic. I’ll even make time for guff like Jaws 4 or Sharknado 5: Global Swarming. I’m metaphorically chumming the water at every opportunity. Every so often, something shows up.
Shark! Celebrity Infested Waters (ITV1, Wednesday 16 July, 9pm) sees seven public figures with a fear of sharks mercilessly pushed into the water to swim with some. Say no more – I’m hooked. The victims – sorry, participants – include Lenny Henry, Lucy Punch, Ross Noble and the bassist from McFly. I like some of these people very much, and hope they don’t mind that I would love them to be ripped in half and devoured in high definition, thrashing about in a vortex of reddening water. It’s nothing personal.
It’s also unlikely, since the show is being aired. (Unless they started with eight contestants.) We are, post-Jaws, more ecologically conscious. There would be massive complaints if the show presented the sharks as primeval nightmare fuel, even though that’s what they are, what ITV wants them to be and what we want them to be. It feels somehow subversive when the consistently hilarious Lucy Punch announces, “I don’t love sharks. I think they’re savage tubes of teeth.”
The show knows that’s why we love them. You can feel it straining against its moral imperative to educate us as to why these beasts are mostly harmless, necessary and misunderstood. “Sharks are the custodians of the sea,” an expert posits at one point. “They take care of the sick, dying and injured.” I imagine this is the same way I “take care of” all the burgers at a barbecue, or foam shrimps at a pick ’n’ mix; I don’t picture the sharks in a Florence Nightingale cap. But the programme doesn’t elaborate, so who’s to say.
In the first hour alone, the celebs experience a rattling encounter with bulls, an alarming flirtation with stingrays, and a frenzy of lemons. They’re mostly uncaged – which doesn’t mean they’re all in the same boat. Paralympian Ade Adepitan does everything the others do with twice the level of physical challenge, while actor Helen George has a phobia of water itself, and hasn’t got in past her knees in 20 years. McFly clearly isn’t afraid of anything, and probably only said he was so he could have a free diving holiday.
I do wonder what the sharks make of this. Can they feel the weight of all our psychic projections? Is that why they don’t sleep? In that sense, Celebrity Infested Waters is a brilliantly cheeky subtitle, flipping the POV. Fame is the opposite of being a shark, really. Irrationally beloved, a lot of celebrities are awful once you understand them.
Rachel Riley and Ade Adepitan with the other celebs in Shark! Celebrity Infested Waters. Photograph: ITV
“This is the realest thing I’ve ever done – and I’ve done panto in Lewisham” quips Henry as the sharks circle. The actors and comedians are pretty charming, and banter gamely on boats, as they overcome their aversion. But it’s George in whom we’re invested. She looks unwell. It’s a reminder that true fear is not visually dramatic. It’s a tense sickness that grips, a private experience of trying to keep an ego from completely fragmenting. I find her panic attack in a cage more affecting and real than any amount of screaming, and I hope she’s OK.
I’m sure she’s heading for epiphany, Punch will learn to love her tubes, and Rachel Riley will be sudoku-ing with a pyjama shark at the end of five episodes. Most people don’t want to stop being afraid of sharks, though. The more convenient our lives become, the more we yearn to imagine overwhelming forces. There’s a paradoxical vitality to it. This truth in no way undermines the importance of marine protections, curbing man’s barbarism, or our commercial predation of the natural world. I’m always on the animals’ side.
Happily – and without spoilers – I can reveal that one of the celebrities does get bitten by a shark in the first episode, and there is a lot of screaming, so everyone’s a winner.
The spring after my A-levels was not going the way I planned. I was 19, hadn’t got the required grades for any of my university choices and hadn’t saved for a gap year. My friends were off enjoying their new lives and I was stuck at home in Essex with my disappointed parents, doing occasional temp work.
Then I read Join Me by the writer and comedian Danny Wallace. I’d enjoyed another book, co-written by him, Are You Dave Gorman?. I found this joyous and silly project, about grownups stumbling their way through their own lives, comforting when I had no direction. So when a friend recommended Join Me, I thought it would be a giggle too; I didn’t realise it would change my life.
The book was more or less about how Wallace inadvertently started a “positivity cult” after posting an ad in a London newspaper that simply said “Join me”. Soon, letters started pouring in. He decided to use these people for good by rallying them to commit random acts of kindness each week. It was the mid-2000s and I spent a lot of time on internet forums. Some people started to talk about the group. The concept appealed, and I duly joined in.
Forum members organised regular real-life Join Me meets, where they would hang out in the pub for most of the day before doing random acts of kindness, such as giving a present to a stranger. I’d been to a couple and, in June 2004, took the train to London for a meet-up on Soho’s Golden Square.
I was always apprehensive about meeting a bunch of strangers I had only spoken to online. One of the first people to approach me was an unassuming, bespectacled, kind-looking young man wearing an awful green jacket. He offered me a homemade Join Me badge – Badge-It! machines were very popular at the time – and we didn’t speak again. We continued chatting on the forum, though, and I ran into him at meets in Brighton and Edinburgh.
Then a few months later, after a night out, I drunkenly started a new thread on the forum, posting that I thought he was quite fit. It was pretty cringe. His reply was something along the lines of: “Erm, thank you?” In the sober light of day we both ignored it.
skip past newsletter promotion
after newsletter promotion
Then on Good Friday 2005, I went to a meet in Nottingham, where he lived. It was the first time we’d met in person since my post, and as we moved from the pub to a club, he yelled out my name, shouted: “I like you, you’re my favourite person!” and ran up to hold my hand. We kissed – and it was the start of the rest of my life.
We texted, and I travelled back to Nottingham and went to a pub quiz with him, then a bowling date, where we had a proper, more sober kiss. After a month of dating, I moved in; five years later we got married.
During that time, I did my resits and got better grades, but I’d met so many people from Join Me who had taken different paths that I realised I didn’t need university at all. I got a job on the local council and made my life in Nottinghamshire with him.
We’ve been married 15 years now. We have a beautiful house, an assortment of cats, fish, sea monkeys and ants, and an amazing 12-year-old son who is the best person I’ve ever met. We still have a tattered copy of Join Me on our bookshelf, and I know of at least 20 human beings who exist because their parents met in that forum.
I am so grateful to Danny Wallace for those silly projects, and particularly how they brought this amazing, kind, funny – and, yes, still quite fit – man into my life.
Over the past two decades, plant science has undergone a revolution. Since the genome of Arabidopsis thaliana was published in 2000, researchers have sequenced more than 1,000 plant species — thanks largely to powerful technologies that were unimaginable just years ago. But this explosion of data has created a new challenge: how to organize, update, and share it all.
Enter PubPlant, a new online database developed by a European research team. Designed to serve as a central hub for plant genomic data, PubPlant not only compiles published genomes but also organizes them, places them in evolutionary context, and updates them regularly.
Published in Frontiers in Plant Science and led by Markus Schwacke, Thomas Usadel, and other experts in bioinformatics and genomics, the project has a bold yet practical goal: to make plant genetic data easily accessible to researchers, students, and agricultural professionals alike.
A Living Map of Plant DNA
What sets PubPlant apart is its commitment to staying current. Unlike traditional reviews, which quickly become outdated, this platform is refreshed monthly with the latest complete genome publications — offering a dynamic, reliable tool for exploring the plant kingdom at the molecular level, according to a press release.
Agriculture and Biodiversity Under the Lens
A quick dive into PubPlant reveals a clear trend: the database heavily features cultivated species. Grains like wheat, rice, and corn, along with legumes such as soybeans and beans, dominate — understandably so, as they form the backbone of global food systems. Families like Solanaceae (potato, tomato) and Brassicaceae (cauliflower, radish) are also well represented.
But PubPlant also exposes the gaps. Countless wild species — from native trees to medicinal herbs — remain underexplored. By highlighting what’s missing, the platform can help direct future research, especially as we search for resilient crops in the face of climate change and food insecurity.
Accessible for All
One of PubPlant’s biggest strengths is its usability. Designed for accessibility, the platform requires no specialized expertise. Users can explore interactive timelines, evolutionary trees, species maps, and direct links to scientific papers — all within a few clicks.
Each species entry includes detailed metadata: scientific name, publication date, genome size, sequencing methods, and links to external databases like Ensembl Plants or NCBI.
A Compass for the Future of Plant Research
The creators of PubPlant emphasize that it’s a free, open, and community-driven resource. Its continued growth relies on scientists sharing new data, suggesting improvements, and using its tools to shape more inclusive and sustainable research.
As agriculture faces mounting challenges — drought, soil degradation, emerging pests — understanding plant genomes isn’t just a scientific endeavor. It’s a strategic priority. PubPlant offers a much-needed compass to navigate the rapidly expanding world of plant genomics.
Federation WH. Deaths from cardiovascular disease surged 60% globally over the last 30 years: Report: World Heart Federation; [updated 23/05/2023; cited 2024 15/10/2024]. Available from: https://world-heart-federation.org/news/deaths-from-cardiovascular-disease-surged-60-globally-over-the-last-30-years-report/
Woodruff RC, Tong X, Khan SS, Shah NS, Jackson SL, Loustalot F, et al. Trends in cardiovascular disease mortality rates and excess deaths, 2010–2022. Am J Prev Med. 2024;66(4):582–9.
PubMed
Google Scholar
Vaduganathan M, Mensah George A, Turco Justine V, Fuster V, Roth GA. The global burden of cardiovascular diseases and risk. J Am Coll Cardiol. 2022;80(25):2361–71.
PubMed
Google Scholar
Nebuwa C, Omoike OJ, Fagbenro A, Uwumiro F, Erhus E, Okpujie V, et al. Rising cardiovascular mortality despite increased resource utilization: insights from the nationwide inpatient sample database. Cureus. 2024;16(4): e57856.
PubMed
PubMed Central
Google Scholar
Chong B, Jayabaskaran J, Jauhari SM, Chan SP, Goh R, Kueh MTW, et al. Global burden of cardiovascular diseases: projections from 2025 to 2050. Eur J Prevent Cardiol. 2024. https://doi.org/10.1093/eurjpc/zwae281.
Google Scholar
Chew NW, Figtree GA, Kong G, Vernon S, Muthiah M, Ng CH, et al. Hepatic steatosis and advanced fibrosis are independent predictors of mortality in acute myocardial infarction without standard modifiable risk factors. Diabetes Obes Metab. 2022;24(12):2454–8.
CAS
PubMed
Google Scholar
Lee EC, Anand VV, Razavi AC, Alebna PL, Muthiah MD, Siddiqui MS, et al. The global epidemic of metabolic fatty liver disease. Curr Cardiol Rep. 2024;26(4):199–210.
PubMed
Google Scholar
Ng CH, Chan KE, Chin YH, Zeng RW, Tsai PC, Lim WH, et al. The effect of diabetes and prediabetes on the prevalence, complications and mortality in nonalcoholic fatty liver disease. Clin Mol Hepatol. 2022;28(3):565.
PubMed
PubMed Central
Google Scholar
Yong JN, Ng CH, Lee CW-M, Chan YY, Tang ASP, Teng M, et al. Non-alcoholic fatty liver disease association with structural heart, systolic and diastolic dysfunction: a meta-analysis. Hepatol Int. 2022;16(2):269–81.
PubMed
Google Scholar
Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Furtado RHM, et al. Comparison of the effects of glucagon-like peptide receptor agonists and sodium-glucose cotransporter 2 inhibitors for prevention of major adverse cardiovascular and renal outcomes in type 2 diabetes mellitus. Circulation. 2019;139(17):2022–31.
CAS
PubMed
Google Scholar
Chew NWS, Mehta A, Goh RSJ, Zhang A, Chen Y, Chong B, et al. Cardiovascular-liver-metabolic health: recommendations in screening, diagnosis, and management of metabolic dysfunction-associated steatotic liver disease in cardiovascular disease via modified Delphi approach. Circulation. 2025;151(1):98–119.
PubMed
Google Scholar
Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311–22.
CAS
PubMed
PubMed Central
Google Scholar
Kueh MT, Chew NW, Al-Ozairi E, le Roux CW. The emergence of obesity in type 1 diabetes. Int J Obes. 2024;48(3):289–301.
Google Scholar
Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389(24):2221–32.
CAS
PubMed
Google Scholar
Heaton J, Alshami A, Imburgio S, Upadhyaya V, Saybolt M, Apolito R, et al. Comparison of pooled cohort equation and PREVENT™ risk calculator for statin treatment allocation. Atherosclerosis. 2024;399: 118626.
CAS
PubMed
Google Scholar
Larkin H. What to know about PREVENT, the AHA’s new cardiovascular disease risk calculator. JAMA. 2024;331(4):277–9.
PubMed
Google Scholar
Chong B, Jayabaskaran J, Ruban J, Goh R, Chin YH, Kong G, et al. Epicardial adipose tissue assessed by computed tomography and echocardiography are associated with adverse cardiovascular outcomes: a systematic review and meta-analysis. Circ Cardiovasc Imaging. 2023;16(5):e015159.
PubMed
Google Scholar
Chew NW, Ng CH, Chan KE, Chee D, Syn N, Tamaki N, et al. FIB-4 predicts MACE and cardiovascular mortality in patients with nonalcoholic fatty liver disease. Can J Cardiol. 2022;38(11):1779–80.
PubMed
Google Scholar
Chew NW, Chong B, Kuo SM, Jayabaskaran J, Cai M, Zheng H, et al. Trends and predictions of metabolic risk factors for acute myocardial infarction: findings from a multiethnic nationwide cohort. The Lancet Regional Health-Western Pacific. 2023;37:100803.
PubMed
PubMed Central
Google Scholar
Virani SS, Newby LK, Arnold SV, Bittner V, Brewer LC, Demeter SH, et al. 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA guideline for the management of patients with chronic coronary disease: a report of the American heart association/American college of cardiology joint committee on clinical practice guidelines. Circulation. 2023;148(9):e9–119.
PubMed
Google Scholar
McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599–726.
CAS
PubMed
Google Scholar
Marx N, Federici M, Schütt K, Müller-Wieland D, Ajjan RA, Antunes MJ, et al. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J. 2023;44(39):4043–140.
CAS
PubMed
Google Scholar
Giugliano D, Scappaticcio L, Longo M, Caruso P, Maiorino MI, Bellastella G, et al. GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes: an updated meta-analysis of eight CVOTs. Cardiovasc Diabetol. 2021;20:1–11.
Google Scholar
Bethel MA, Patel RA, Merrill P, Lokhnygina Y, Buse JB, Mentz RJ, et al. Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis. Lancet Diabetes Endocrinol. 2018;6(2):105–13.
PubMed
Google Scholar
Leite AR, Angélico-Gonçalves A, Vasques-Nóvoa F, Borges-Canha M, Leite-Moreira A, Neves JS, et al. Effect of glucagon-like peptide-1 receptor agonists on cardiovascular events in overweight or obese adults without diabetes: a meta-analysis of placebo-controlled randomized trials. Diabetes Obes Metab. 2022;24(8):1676–80.
CAS
PubMed
Google Scholar
Rivera FB, Cruz LLA, Magalong JV, Ruyeras JMMJ, Aparece JP, Bantayan NRB, et al. Cardiovascular and renal outcomes of glucagon-like peptide 1 receptor agonists among patients with and without type 2 diabetes mellitus: a meta-analysis of randomized placebo-controlled trials. Am J Prevent Cardiol. 2024;18: 100679.
Google Scholar
Paule RC, Mandel J. Consensus values and weighting factors. J Res Natl Bur Stand. 1982;87(5):377.
Harrer M, Cuijpers P, Furukawa T, Ebert D. Doing meta-analysis with R: A hands-on guide. Boca Raton: Chapman and Hall/CRC; 2021.
Google Scholar
Weber F, Knapp G, Ickstadt K, Kundt G, Glass Ä. Zero-cell corrections in random-effects meta-analyses. Res Synth Methods. 2020;11(6):913–9.
PubMed
Google Scholar
Deeks JJ, Higgins JP, Altman DG, Group CSM. Analysing data and undertaking meta‐analyses. Cochrane handbook for systematic reviews of interventions. 2019;241–84.
Tufanaru C, Munn Z, Stephenson M, Aromataris E. Fixed or random effects meta-analysis? Common methodological issues in systematic reviews of effectiveness. JBI Evidence Implementation. 2015;13(3):196–207.
Google Scholar
Bell A, Fairbrother M, Jones K. Fixed and random effects models: making an informed choice. Qual Quant. 2019;53:1051–74.
Google Scholar
Higgins JP, Savović J, Page MJ, Elbers RG, Sterne JA. Assessing risk of bias in a randomized trial. In: Cochrane handbook for systematic reviews of interventions 2019; pp 205–28.
IntHout J, Ioannidis JP, Borm GF. The Hartung-Knapp-Sidik-Jonkman method for random effects meta-analysis is straightforward and considerably outperforms the standard DerSimonian-Laird method. BMC Med Res Methodol. 2014;14:1–12.
Google Scholar
Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629–34.
CAS
PubMed
PubMed Central
Google Scholar
Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336(7650):924–6.
PubMed
PubMed Central
Google Scholar
Ruff CT, Baron M, Im K, O’Donoghue ML, Fiedorek FT, Sabatine MS. Subcutaneous infusion of exenatide and cardiovascular outcomes in type 2 diabetes: a non-inferiority randomized controlled trial. Nat Med. 2022;28(1):89–95.
CAS
PubMed
Google Scholar
Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. The Lancet. 2019;394(10193):121–30.
CAS
Google Scholar
Pfeffer MA, Claggett B, Diaz R, Dickstein K, Gerstein HC, Køber LV, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med. 2015;373(23):2247–57.
CAS
PubMed
Google Scholar
Green JB, Everett BM, Ghosh A, Younes N, Krause-Steinrauf H, Barzilay J, et al. Cardiovascular outcomes in GRADE (Glycemia reduction approaches in type 2 diabetes: a comparative effectiveness study). Circulation. 2024;149(13):993–1003.
CAS
PubMed
PubMed Central
Google Scholar
Del Prato S, Kahn SE, Pavo I, Weerakkody GJ, Yang Z, Doupis J, et al. Efficacy and safety of tirzepatide versus insulin glargine in patients with type 2 diabetes and increased cardiovascular risk (SURPASS-4). Diabetologie und Stoffwechsel. 2022;17(01):008.
Google Scholar
Pei Y, Agner BR, Luo B, Dong X, Li D, Liu J, et al. DUAL II China: Superior HbA1c reductions and weight loss with insulin degludec/liraglutide (IDegLira) versus insulin degludec in a randomized trial of Chinese people with type 2 diabetes inadequately controlled on basal insulin. Diabetes Obes Metab. 2021;23(12):2687–96.
CAS
PubMed
PubMed Central
Google Scholar
Frias JP, Wynne AG, Matyjaszek-Matuszek B, Bartaskova D, Cox DA, Woodward B, et al. Efficacy and safety of an expanded dulaglutide dose range: a phase 2, placebo-controlled trial in patients with type 2 diabetes using metformin. Diabetes Obes Metab. 2019;21(9):2048–57.
CAS
PubMed
Google Scholar
Philis-Tsimikas A, Billings LK, Busch R, Portillo CM, Sahay R, Halladin N, et al. Superior efficacy of insulin degludec/liraglutide versus insulin glargine U100 as add-on to sodium-glucose co-transporter-2 inhibitor therapy: a randomized clinical trial in people with uncontrolled type 2 diabetes. Diabetes Obes Metab. 2019;21(6):1399–408.
CAS
PubMed
PubMed Central
Google Scholar
Seino Y, Terauchi Y, Osonoi T, Yabe D, Abe N, Nishida T, et al. Safety and efficacy of semaglutide once weekly vs sitagliptin once daily, both as monotherapy in Japanese people with type 2 diabetes. Diabetes Obes Metab. 2018;20(2):378–88.
CAS
PubMed
Google Scholar
Jabbour SA, Frias JP, Hardy E, Ahmed A, Wang H, Öhman P, et al. Safety and efficacy of exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy: 52-week results of the DURATION-8 randomized controlled trial. Diabetes Care. 2018;41(10):2136–46.
CAS
PubMed
PubMed Central
Google Scholar
Le Roux CW, Astrup A, Fujioka K, Greenway F, Lau DC, Van Gaal L, et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. The Lancet. 2017;389(10077):1399–409.
Google Scholar
Araki E, Inagaki N, Tanizawa Y, Oura T, Takeuchi M, Imaoka T. Efficacy and safety of once-weekly dulaglutide in combination with sulphonylurea and/or biguanide compared with once-daily insulin glargine in Japanese patients with type 2 diabetes: a randomized, open-label, phase III, non-inferiority study. Diabetes Obes Metab. 2015;17(10):994–1002.
CAS
PubMed
PubMed Central
Google Scholar
Gough SC, Bode B, Woo V, Rodbard HW, Linjawi S, Poulsen P, et al. Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes. Lancet Diabetes Endocrinol. 2014;2(11):885–93.
CAS
PubMed
Google Scholar
Yu Pan C, Han P, Liu X, Yan S, Feng P, Zhou Z, et al. Lixisenatide treatment improves glycaemic control in Asian patients with type 2 diabetes mellitus inadequately controlled on metformin with or without sulfonylurea: a randomized, double-blind, placebo-controlled, 24-week trial (GetGoal-M-Asia). Diabetes Metab Res Rev. 2014;30(8):726–35.
PubMed
Google Scholar
Riddle MC, Forst T, Aronson R, Sauque-Reyna L, Souhami E, Silvestre L, et al. Adding once-daily lixisenatide for type 2 diabetes inadequately controlled with newly initiated and continuously titrated basal insulin glargine: a 24-week, randomized, placebo-controlled study (GetGoal-Duo 1). Diabetes Care. 2013;36(9):2497–503.
CAS
PubMed
PubMed Central
Google Scholar
Gerstein HC, Li Z, Ramasundarahettige C, Baek S, Branch KR, Del Prato S, et al. Exploring the relationship between efpeglenatide dose and cardiovascular outcomes in type 2 diabetes: insights from the AMPLITUDE-O trial. Circulation. 2023;147(13):1004–13.
CAS
PubMed
Google Scholar
Gerstein HC, Sattar N, Rosenstock J, Ramasundarahettige C, Pratley R, Lopes RD, et al. Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes. N Engl J Med. 2021;385(10):896–907.
CAS
PubMed
Google Scholar
Holman RR, Bethel MA, Mentz RJ, Thompson VP, Lokhnygina Y, Buse JB, et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2017;377(13):1228–39.
CAS
PubMed
PubMed Central
Google Scholar
Hernandez AF, Green JB, Janmohamed S, D’Agostino RB, Granger CB, Jones NP, et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. The Lancet. 2018;392(10157):1519–29.
CAS
Google Scholar
Husain M, Birkenfeld AL, Donsmark M, Dungan K, Eliaschewitz FG, Franco DR, et al. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2019;381(9):841–51.
CAS
PubMed
Google Scholar
Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834–44.
CAS
PubMed
Google Scholar
Pinget M, Goldenberg R, Niemoeller E, Muehlen-Bartmer I, Guo H, Aronson R. Efficacy and safety of lixisenatide once daily versus placebo in type 2 diabetes insufficiently controlled on pioglitazone (GetGoal-P). Diabetes Obes Metab. 2013;15(11):1000–7.
CAS
PubMed
Google Scholar
Perkovic V, Tuttle KR, Rossing P, Mahaffey KW, Mann JF, Bakris G, et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. N Engl J Med. 2024;391(2):109–21.
CAS
PubMed
Google Scholar
McGuire DK, Marx N, Mulvagh SL, Deanfield JE, Inzucchi SE, Pop-Busui R, et al. Oral Semaglutide and cardiovascular outcomes in high-risk type 2 diabetes. N Engl J Med. 2025;392(20):2001–12.
CAS
PubMed
Google Scholar
DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177–88.
CAS
PubMed
Google Scholar
Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American college of cardiology/American heart association task force on clinical practice guidelines. Circulation. 2019;140(11):e596–646.
PubMed
PubMed Central
Google Scholar
Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: The Task Force for diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD). Eur Heart J. 2019;41(2):255–323.
Google Scholar
Kong G, Chin YH, Chong B, Goh RSJ, Lim OZH, Ng CH, et al. Higher mortality in acute coronary syndrome patients without standard modifiable risk factors: results from a global meta-analysis of 1,285,722 patients. Int J Cardiol. 2023;371:432–40.
PubMed
Google Scholar
Kong G, Chew NW, Ng CH, Chin YH, Lim OZ, Ambhore A, et al. Prognostic outcomes in acute myocardial infarction patients without standard modifiable risk factors: a multiethnic study of 8,680 Asian patients. Front Cardiovasc Med. 2022;9: 869168.
PubMed
PubMed Central
Google Scholar
Figtree GA, Vernon ST, Harmer JA, Gray MP, Arnott C, Bachour E, et al. Clinical pathway for coronary atherosclerosis in patients without conventional modifiable risk factors: JACC State-of-the-Art Review. J Am Coll Cardiol. 2023;82(13):1343–59.
PubMed
PubMed Central
Google Scholar
Kong G, Chew NW, Ng CH, Chin YH, Zeng R, Foo R, et al. Long-term outcomes in acute coronary syndrome patients without standard modifiable risk factors: a multi-ethnic retrospective cohort study of 5400 Asian patients. J Thromb Thrombolysis. 2022;54(4):569–78.
PubMed
Google Scholar
Park B, Bakbak E, Teoh H, Krishnaraj A, Dennis F, Quan A, et al. GLP-1 receptor agonists and atherosclerosis protection: the vascular endothelium takes center stage. Am J Physiol Heart Circ Physiol. 2024;326(5):H1159–76.
CAS
PubMed
Google Scholar
Tan B, Pan X-H, Chew HSJ, Goh RSJ, Lin C, Anand VV, et al. Efficacy and safety of tirzepatide for treatment of overweight or obesity. A systematic review and meta-analysis. Int J Obes. 2023;47(8):677–85.
CAS
Google Scholar
Chew NW, Ng CH, Muthiah MD, Sanyal AJ. Comprehensive review and updates on holistic approach towards non-alcoholic fatty liver disease management with cardiovascular disease. Curr Atheroscler Rep. 2022;24(7):515–32.
CAS
PubMed
Google Scholar
Chew NW, Ng CH, Truong E, Noureddin M, Kowdley KV, editors. Nonalcoholic steatohepatitis drug development pipeline: an update. Seminars in Liver Disease; 2022: Thieme Medical Publishers, Inc.
Zheng SL, Roddick AJ. Association of aspirin use for primary prevention with cardiovascular events and bleeding events: a systematic review and meta-analysis. JAMA. 2019;321(3):277–87.
CAS
PubMed
PubMed Central
Google Scholar
David Newman M. Statin Drugs given for 5 years for heart disease prevention (without known heart disease) 2015 [updated January 10, 2015. Available from: https://thennt.com/nnt/statins-for-heart-disease-prevention-without-prior-heart-disease-2/.
James McCormack MP-RbRR, MD and Barbara Roberts, MD. Blood Pressure Medicines for Five Years to Prevent Death, Heart Attacks, and Strokes 2014 [updated July 21, 2014. Available from: https://thennt.com/nnt/anti-hypertensives-to-prevent-death-heart-attacks-and-strokes/.
Trevisan M, Fu EL, Szummer K, Norhammar A, Lundman P, Wanner C, et al. Glucagon-like peptide-1 receptor agonists and the risk of cardiovascular events in diabetes patients surviving an acute myocardial infarction. Eur Heart J Cardiovasc Pharmacother. 2021;7(2):104–11.
PubMed
Google Scholar
De Filippo O, D’Ascenzo F, Iannaccone M, Bertaina M, Leone A, Borzillo I, et al. Safety and efficacy of bempedoic acid: a systematic review and meta-analysis of randomised controlled trials. Cardiovasc Diabetol. 2023;22(1):324.
PubMed
PubMed Central
Google Scholar
Sheahan KH, Wahlberg EA, Gilbert MP. An overview of GLP-1 agonists and recent cardiovascular outcomes trials. Postgrad Med J. 2020;96(1133):156–61.
PubMed
Google Scholar
Chin YH, Lim O, Lin C, Chan YY, Kong G, Ng CH, et al. Meta-analysis of the placebo and nocebo effects associated with placebo treatment in randomized trials of lipid-lowering therapies. Eur Heart J Quality Care Clin Outcomes. 2023;9(5):511–9.
Google Scholar
Yaow CYL, Chong B, Chin YH, Kueh MTW, Ng CH, Chan KE, et al. Higher risk of adverse cardiovascular outcomes in females with type 2 diabetes Mellitus: an Umbrella review of systematic reviews. Eur J Prev Cardiol. 2023;30(12):1227–35.
PubMed
Google Scholar
Bogers RP, Bemelmans WJ, Hoogenveen RT, Boshuizen HC, Woodward M, Knekt P, et al. Association of overweight with increased risk of coronary heart disease partly independent of blood pressure and cholesterol levels: a meta-analysis of 21 cohort studies including more than 300 000 persons. Arch Intern Med. 2007;167(16):1720–8.
PubMed
Google Scholar
Adams B, Jacocks L, Guo H. Higher BMI is linked to an increased risk of heart attacks in European adults: a Mendelian randomisation study. BMC Cardiovasc Disord. 2020;20:1–8.
Google Scholar
Dar S, Siddiqi AK, Alabduladhem TO, Rashid AM, Sarfraz S, Maniya T, et al. Effects of novel glucose-lowering drugs on the lipid parameters: a systematic review and meta-analysis. Ann Med Surg. 2022;77: 103633.
Google Scholar
Fu CE, Ng CH, Yong JN, Chan KE, Xiao J, Nah B, et al. A meta-analysis on associated risk of mortality in nonalcoholic fatty liver disease. Endocr Pract. 2023;29(1):33–9.
PubMed
Google Scholar
Chan KE, Ng CH, Fu CE, Quek J, Kong G, Goh YJ, et al. The spectrum and impact of metabolic dysfunction in MAFLD: a longitudinal cohort analysis of 32683 overweight and obese individuals. Clin Gastroenterol Hepatol. 2023;21(10):2560-9.e15.
CAS
PubMed
Google Scholar
Kong G, Zhang A, Chong B, Lim J, Kannan S, Han Chin Y, et al. Long-term prognosis of patients with coexisting obesity and malnutrition after acute myocardial infarction: a cohort study. Circ Cardiovasc Quality Outcomes. 2023;16(4):e009340.
Google Scholar
Kong G, Chin YH, Lim J, Ng CH, Kannan S, Chong B, et al. A two-decade population-based study on the effect of hypertension in the general population with obesity in the United States. Obesity. 2023;31(3):832–40.
PubMed
Google Scholar
Xiao J, Ng CH, Chan KE, Fu C, Tay P, Yong JN, et al. Hepatic, extra-hepatic outcomes and causes of mortality in NAFLD–an umbrella overview of systematic review of meta-analysis. J Clin Exp Hepatol. 2023;13(4):656–65.
CAS
PubMed
Google Scholar
Fernando K, Bain SC, Holmes P, Jones PN, Patel DC. Glucagon-like peptide 1 receptor agonist usage in type 2 diabetes in primary care for the UK and beyond: a narrative review. Diabetes Therapy. 2021;12(9):2267–88.
CAS
PubMed
PubMed Central
Google Scholar
Marx N, Husain M, Lehrke M, Verma S, Sattar N. GLP-1 receptor agonists for the reduction of atherosclerotic cardiovascular risk in patients with type 2 diabetes. Circulation. 2022;146(24):1882–94.
CAS
PubMed
Google Scholar
Wright AK, Carr MJ, Kontopantelis E, Leelarathna L, Thabit H, Emsley R, et al. Primary prevention of cardiovascular and heart failure events with SGLT2 inhibitors, GLP-1 receptor agonists, and their combination in type 2 diabetes. Diabetes Care. 2022;45(4):909–18.
CAS
PubMed
Google Scholar
Chew NW, Kong G, Venisha S, Chin YH, Ng CH, Muthiah M, et al. Long-term prognosis of acute myocardial infarction associated with metabolic health and obesity status. Endocr Pract. 2022;28(8):802–10.
PubMed
Google Scholar
Lin C, Loke WH, Ng BH, Chin YH, Chong B, Goh RSJ, et al. Mortality, cardiovascular, and medication outcomes in patients with myocardial infarction and underweight in a meta-analysis of 6.3 million patients. Am J Cardiol. 2023;196:1–10.
PubMed
Google Scholar
Chew NW, Pan XH, Chong B, Chandramouli C, Muthiah M, Lam CS. Type 2 diabetes mellitus and cardiometabolic outcomes in metabolic dysfunction-associated steatotic liver disease population. Diabetes Res Clin Pract. 2024;211: 111652.
CAS
PubMed
Google Scholar
Lai AR, Warrier M, Ng EZ, Lin C, Chin YH, Kong G, et al. Cardiovascular outcomes in acute coronary syndrome and malnutrition: a meta-analysis of nutritional assessment tools. JACC Adv. 2023;2(8):100635.
PubMed
PubMed Central
Google Scholar
Sattar N, Lee MMY, Kristensen SL, Branch KRH, Del Prato S, Khurmi NS, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. Lancet Diabetes Endocrinol. 2021;9(10):653–62.
CAS
PubMed
Google Scholar
Villaschi A, Ferrante G, Cannata F, Pini D, Pagnesi M, Corrada E, et al. GLP-1-ra and heart failure-related outcomes in patients with and without history of heart failure: an updated systematic review and meta-analysis. Clin Res Cardiol. 2024;113(6):898–909.
PubMed
Google Scholar
Marfella R, Prattichizzo F, Sardu C, Rambaldi PF, Fumagalli C, Marfella LV, et al. GLP-1 receptor agonists-SGLT-2 inhibitors combination therapy and cardiovascular events after acute myocardial infarction: an observational study in patients with type 2 diabetes. Cardiovasc Diabetol. 2024;23(1):10.
CAS
PubMed
PubMed Central
Google Scholar
Marfella R, Rizzo MR, Siniscalchi M, Paolisso P, Barbieri M, Sardu C, et al. Peri-procedural tight glycemic control during early percutaneous coronary intervention up-regulates endothelial progenitor cell level and differentiation during acute ST-elevation myocardial infarction: effects on myocardial salvage. Int J Cardiol. 2013;168(4):3954–62.
PubMed
Google Scholar
Paolisso P, Bergamaschi L, Santulli G, Gallinoro E, Cesaro A, Gragnano F, et al. Infarct size, inflammatory burden, and admission hyperglycemia in diabetic patients with acute myocardial infarction treated with SGLT2-inhibitors: a multicenter international registry. Cardiovasc Diabetol. 2022;21(1):77.
CAS
PubMed
PubMed Central
Google Scholar
Muthiah M, Ng CH, Chan KE, Fu CE, Lim WH, Tan DJH, et al. Type 2 diabetes mellitus in metabolic-associated fatty liver disease versus type 2 diabetes mellitus non-alcoholic fatty liver disease: a longitudinal cohort analysis. Ann Hepatol. 2023;28(1):100762.
CAS
PubMed
Google Scholar
Chin YH, Ng CH, Chew NW, Kong G, Lim WH, Tan DJH, et al. The placebo response rate and nocebo events in obesity pharmacological trials. A systematic review and meta-analysis. EClinicalMedicine. 2022;54.
Llewellyn DC, Logan Ellis H, Aylwin SJ, Oštarijaš E, Green S, Sheridan W, et al. The efficacy of GLP-1RAs for the management of postprandial hypoglycemia following bariatric surgery: a systematic review. Obesity. 2023;31(1):20–30.
CAS
PubMed
Google Scholar
Yeong T, Mai AS, Lim OZ, Ng CH, Chin YH, Tay P, et al. Can glucose-lowering medications improve outcomes in non-diabetic heart failure patients? A Bayesian network meta-analysis. ESC Heart Failure. 2022;9(2):1338–50.
PubMed
PubMed Central
Google Scholar
Chew NW, Ng C-H, Kong G, Lee K-S, Tan DJ, Lim OZ-H, et al. Meta-analysis of percutaneous coronary intervention versus coronary artery bypass grafting for left main narrowing. Am J Cardiol. 2022;173:39–47.
PubMed
Google Scholar
Alebna PL, Han CY, Ambrosio M, Kong G, Cyrus JW, Harley K, et al. Association of Lipoprotein (a) with major adverse cardiovascular events across hs-CRP: a systematic review and meta-analysis. JACC Adv. 2024;3(12_Part_1):101409.
PubMed
PubMed Central
Google Scholar
Rodriguez PJ, Zhang V, Gratzl S, Do D, Goodwin Cartwright B, Baker C, et al. Discontinuation and reinitiation of dual-labeled glp-1 receptor agonists among US adults with overweight or obesity. JAMA Netw Open. 2025;8(1): e2457349.
PubMed
PubMed Central
Google Scholar
Durden E, Liang M, Fowler R, Panton UH, Mocevic E. The effect of early response to GLP-1 RA therapy on long-term adherence and persistence among type 2 diabetes patients in the United States. J Manag Care Spec Pharm. 2019;25(6):669–80.
PubMed
Google Scholar
Weiss T, Carr RD, Pal S, Yang L, Sawhney B, Boggs R, et al. Real-world adherence and discontinuation of glucagon-like peptide-1 receptor agonists therapy in type 2 diabetes mellitus patients in the United States. Patient Prefer Adherence. 2020;14:2337–45.
PubMed
PubMed Central
Google Scholar
Gasoyan H, Pfoh ER, Schulte R, Le P, Rothberg MB. Early- and later-stage persistence with antiobesity medications: a retrospective cohort study. Obesity (Silver Spring). 2024;32(3):486–93.
PubMed
Google Scholar
Do D, Lee T, Peasah SK, Good CB, Inneh A, Patel U. GLP-1 receptor agonist discontinuation among patients with obesity and/or type 2 diabetes. JAMA Netw Open. 2024;7(5):e2413172-e.
Despite the loss, Kyle Filipowski led all scorers in on Day 6 of summer league action with 32 points in Las Vegas
• Download the NBA App • Summer League: Complete Coverage
Day 2 in Las Vegas brought huge performances, with many prospects hungry to compete to showcase their versatility at the NBA 2K26 Summer League.
Here are the standouts from Day 2 of Las Vegas with rookies and returning players rounding out the list:
Kobe Bufkin, Atlanta Hawks
Nobody made use of the free-throw line like Kobe Bufkin in a 105-98 win against the Heat. Bufkin led all scorers with 29 points, and 15 of those points came at the charity stripe.
Bufkin is a downhill guard who has no problem using his athleticism to draw fouls around the rim. Bufkin shot 100% from line, also totaling three rebounds, three assists and two blocks. Bufkin is going into his third season in the NBA, but injuries have limited Bufkin to only 27 games in two seasons. Bufkins’ game high, propelled the Hawks to a late fourth quarter win.
Liam McNeeley, Charlotte Hornets
Coming off the bench, McNeeley led the Hornets in scoring and rebounding totaling 22 points and 12 rebounds. McNeeley also showed his range, shooting 3-for-5 from beyond the arc while leading the Hornets to a 111-105 win against the Jazz. McNeeley is a two-way player, an aggressive defender at 6-foot-7, whose skill sets were on full display in his Summer League debut.
Kyle Filipowski, Utah Jazz
Despite the loss, Filipowski’s talent was on full display, dropping an NBA 2K26 Summer League high (so far!) in Utah’s 111-105 loss, totaling 32 points shooting 3-for-7 from beyond the arc.
He also showed his rebounding and playmaking ability adding six rebounds, and five assists. After Filipowski’s 20-point performances in Salt Lake, he was selected as one of the 15 players to watch coming into Las Vegas. Thus far, he has exceeded expectations going into his sophomore season.
AJ Lawson, Toronto Raptors
Lawson came off the bench firing hot from beyond the arc, shooting 4-for-8 from 3. Lawson totaled 22 points, six rebounds and two steals in the 116-72 win against the Bulls. Lawson led all scorers in points, showing his poise around the rim. The 6-foot-6 guard showed his versatility finishing inside and knocked down shots in rhythm, clearly the hot hand for Toronto tonight.
Ron Holland II, Detroit Pistons
Holland II’s game-high 28-point, 11-rebound double-double led the Pistons to a 104-86 win against the Knicks. Holland took over in the third quarter, scoring 18 of his 28 points and knocking down all three of his 3-pointers. Holland II revealed many sides to his game, also driving downhill to make plays around the cup.
Reed Sheppard, Houston Rockets
Despite the Rockets’ 95-92 loss, Reed Sheppard led all scorers with 28 points, showcasing his sharp shooting ability from beyond the arc. Sheppard shot 40.0% from 3-point range on 15 attempts while also collecting eight rebounds, four assists, four steals and three blocks. Sheppard scored 13 of his 28 points in the third quarter, and though he went scoreless in the fourth, the second-year guard seems primed to fulfill a bigger role on the Rockets this season.
BAJAUR – The funeral prayer of Maulana Khan Zeb, senior leader of the Awami National Party (ANP) and Secretary for Religious Affairs, was held in his native town of Nawagai, a day after he was shot and killed.
A large crowd of mourners, including thousands of locals, political workers, and tribal elders, attended the funeral. Prominent attendees included ANP’s provincial president Mian Iftikhar Hussain, senior leader Sardar Hussain Babak, MNAs from Bajaur Nisar Baz, Dr. Hameed, and Anwar Zeb Khan. Maulana Khan Zeb was laid to rest in his hometown, and emotional scenes with tearful attendees marked the funeral. Earlier in the day, the funeral of police constable Sherzada, who was also killed in the same incident, was held with a large public turnout paying respects to the fallen officer.
The Human Rights Commission of Pakistan (HRCP) issued a statement condemning the killing, hailing Khan Zeb as “a leading peace campaigner and political leader of the ANP”. “We demand a swift and impartial inquiry into this tragic incident,” the rights body wrote in a statement on X. Meanwhile, Prime Minister Shehbaz Sharif on Friday expressed his grief over the assassination of Awami National Party leader Maulana Khan Zeb in a targeted attack in Bajaur that took place on Thursday. Remembering the slain ANP leader as a “very fine soul, and a staunch advocate for peace,” the prime minister wrote on X that he was “grieved to learn about the assassination of Maulana Khan Zeb in a cowardly targeted attack in Bajaur.” He extended his heartfelt condolences to the grieved family, colleagues, and the people of Bajaur and prayed for peace for the departed soul.